Anti-Aging
Human Longevity Inc.'s Brad Perkins says technological innovations including cloud-based systems could spark a medical revolution in tackling age-related diseases.
Brad Perkins is a visionary physician, scientist, and executive who is responsible for leading all clinical and therapeutic operations at the Human Longevity Inc. This includes collecting and utilizing phenotype data, development of the consumer clinics business, and guiding stem cell therapeutics.
"With machine learning, scientists can connect medical genome to sequence data and, therefore, understand the fundamental causes of aging."
According to Perkins, technological innovations including cloud-based systems could spark a medical revolution in tackling age-related diseases.Research into diseases such as Alzheimer's, diabetes and cancer could be advanced by new technology and could potentially see the human lifespan eventually double, states Perkins, who spoke at this year's World Government Summit in Dubai.
Technology cited included integrated data bases, cloud-based systems, advanced clinical imaging and machine, which could help improve knowledge of the human genome.
“With machine learning, scientists can connect medical genome to sequence data and, therefore, understand the fundamental causes of aging. By comparing physiological to chronological age and building direct medical intervention methods for age, we are closer to preventing age related diseases.”
Related articles
Prior to joining HLI, Dr. Perkins was Executive Vice President for Strategy and Innovation, and Chief Transformation Officer at Vanguard Health Systems, a large multi-state, for-profit, integrated health services provider with nearly 46,000 employees. He helped transform Vanguard from a traditional fee for service healthcare model, to a fee for value, “population health” model. Some of his innovative solutions there included: establishing Accountable Care Organizations to improve primary care, implementing an award winning tele-radiology program, and starting a $167 million venture capital fund to support Vanguard’s transformation programs.Dr. Perkins began his career at the Centers for Disease Control and Prevention (CDC) in 1989 after completing his residency training and chief residency in internal medicine at Baylor College of Medicine. At the CDC he led some of the most important and high profile programs and published more than 120 peer-reviewed publications and book chapters.
He first joined and then led the Meningitis and Special Pathogens Branch where he investigated global bacterial disease epidemics. He co-discovered the bacteria which causes Cat Scratch Diseases and conducted translational research leading to development of several new bacterial meningitis and pneumonia vaccines. In 2001 Dr. Perkins led the investigations into the anthrax attacks in the United States, the largest and highest profile investigation ever conducted by CDC. In 2005 he was appointed CDC’s Chief Strategy and Innovation Officer, a position in which he managed a $11.2 billion budget, and 15,000 employees with offices in more than 50 countries. Working closely with the CDC Director, he built a $2 billion state-of-the-art emergency response capability and positioned the improvement of population health as a focus of the healthcare reform movement within the White House administration at that time.
Dr. Perkins is a member of the RAND Health Board, and he is the chairman of the advisory board for Esther Dyson’s nonprofit, HICCup, sponsor of the “Way to Wellville” community health competition. He received his BA in Microbiology and his MD from the University of Missouri-Columbia, and an MBA from Emory University. He is Board Certified in Internal Medicine.
per year by 2020. "I’d like to see that number higher," Perkins says.
